Okay, here’s a draft article based on the provided text, adhering to all the specified requirements.⁢ I’ve added the required components, formatting, and attempted to meet the‍ E-E-A-T guidelines. I’ve also‍ expanded slightly to provide⁣ more context‌ where appropriate.

“`html

FDA ⁢Turmoil Continues: top Regulator Retires After Just Weeks

The Food and ‍Drug Administration (FDA) continues ‍to experience notable upheaval under the leadership​ of RFK Jr.’s appointees. Just⁣ weeks after being appointed to restore stability, ⁣Richard Pazdur, a veteran of over 25 years at the⁢ agency, has announced​ his retirement as Director of the Center for drug Evaluation and Research⁣ (CDER).

This follows the resignation of George Tidmarsh in November 2025, who ⁢was accused of using his position to target a former business partner.Tidmarsh’s tenure lasted less than six months. Pazdur’s departure, occurring a mere two-and-a-half “Scaramucci’s” after ‌his appointment (a Scaramucci being ​defined as 11 days,⁤ referencing Anthony Scaramucci’s brief time as White ⁤House ⁢Communications Director), underscores the deep dysfunction within the agency.

the Tidmarsh Precedent

The situation began with allegations against George Tidmarsh, who joined ‌the FDA in July 2025 as chief drug regulator.​ he was accused of a ⁢vendetta‌ campaign against ​Kevin​ Tang, stemming⁢ from a past business dispute. Tang alleged that‌ Tidmarsh attempted to leverage drug ingredient ⁢approvals in exchange for financial contributions⁤ to an association associated with Tidmarsh.

Pazdur’s Brief Tenure and Unexpected Exit

Richard Pazdur was initially seen as a stabilizing force. His ⁢appointment was widely‍ praised within the medical community, with many viewing him as a highly⁣ qualified and experienced professional. Such ​as:

Cancer⁣ Nation applauds‌ the choice ⁢of Dr. richard⁣ Pazdur ⁤as the Director ⁢of the Center for Drug​ Evaluation and Research (CDER) at the Food‌ and​ Drug ​Administration (FDA). We can think of no better person than ⁢Dr. Pazdur for this position, as he will bring scientific rigor, evidence-based regulatory review, ‌and a commitment ‍to patients to his ⁢work as CDER head.

“We are grateful ‍that someone with both scientific rigor and lived compassion will be leading CDER, and we look forward to continuing our shared work to make sure every survivor gets the care ‍they ‌need to live well,” said Shelley Fuld Nasso, ‍Cancer Nation CEO.